Febrile neutropenia rates with adjuvant docetaxel and cyclophosphamide chemotherapy in early breast cancer: discrepancy between published reports and community practice-a retrospective analysis.
作者信息
Vandenberg T, Younus J, Al-Khayyat S
机构信息
London Regional Cancer Program, London, Ontario.
出版信息
Curr Oncol. 2010 Apr;17(2):2-3. doi: 10.3747/co.v17i2.498.
Abstract
摘要
相似文献
1
Febrile neutropenia rates with adjuvant docetaxel and cyclophosphamide chemotherapy in early breast cancer: discrepancy between published reports and community practice-a retrospective analysis.
Curr Oncol. 2010 Apr;17(2):2-3. doi: 10.3747/co.v17i2.498.
2
Febrile neutropenia rates with adjuvant docetaxel and cyclophosphamide chemotherapy in early breast cancer: discrepancy between published reports and community practice-an updated analysis.
Curr Oncol. 2012 Dec;19(6):332-4. doi: 10.3747/co.19.1174.
3
Low-dose filgrastim in patients with breast cancer treated with docetaxel, doxorubicin, and cyclophosphamide.
Am J Health Syst Pharm. 2008 Aug 15;65(16):1552-5. doi: 10.2146/ajhp070489.
4
Clinical Outcomes and Cost-effectiveness of Primary Prophylaxis of Febrile Neutropenia During Adjuvant Docetaxel and Cyclophosphamide Chemotherapy for Breast Cancer.
Breast J. 2015 Nov-Dec;21(6):658-64. doi: 10.1111/tbj.12501. Epub 2015 Sep 20.
5
Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial.
Ann Oncol. 2016 Jun;27(6):1041-1047. doi: 10.1093/annonc/mdw098. Epub 2016 Mar 2.
6
The risk of febrile neutropenia and need for G-CSF primary prophylaxis with the docetaxel and cyclophosphamide regimen in early-stage breast cancer patients: a meta-analysis.
Breast Cancer Res Treat. 2015 Oct;153(3):591-7. doi: 10.1007/s10549-015-3531-z. Epub 2015 Sep 4.
7
Risk of emergency hospitalisation and survival outcomes following adjuvant chemotherapy for early breast cancer in New South Wales, Australia.
Eur J Cancer Care (Engl). 2019 Sep;28(5):e13125. doi: 10.1111/ecc.13125. Epub 2019 Jun 21.
8
Weak circadian rhythm increases neutropenia risk among breast cancer patients undergoing adjuvant chemotherapy.
Breast Cancer Res Treat. 2018 Apr;168(2):483-493. doi: 10.1007/s10549-017-4614-9. Epub 2017 Dec 11.
9
Is febrile neutropenia prophylaxis with granulocyte-colony stimulating factors economically justified for adjuvant TC chemotherapy in breast cancer?
Support Care Cancer. 2016 Jan;24(1):387-394. doi: 10.1007/s00520-015-2805-7. Epub 2015 Jun 17.
10
Incidence of Febrile Neutropenia in Korean Female Breast Cancer Patients Receiving Preoperative or Postoperative Doxorubicin/Cyclophosphamide Followed by Docetaxel Chemotherapy.
J Breast Cancer. 2016 Mar;19(1):76-82. doi: 10.4048/jbc.2016.19.1.76. Epub 2016 Mar 25.
引用本文的文献
1
A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia.
Breast. 2021 Aug;58:42-49. doi: 10.1016/j.breast.2021.03.012. Epub 2021 Apr 1.
2
Early neutropenia on day 8 treated with adjuvant Docetaxel-based chemotherapy in early breast cancer patients: Putative mechanisms within the neutrophil pool system.
PLoS One. 2019 Apr 18;14(4):e0215576. doi: 10.1371/journal.pone.0215576. eCollection 2019.
3
Feasibility of using a pragmatic trials model to compare two primary febrile neutropenia prophylaxis regimens (ciprofloxacin versus G-CSF) in patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer (REaCT-TC).
Support Care Cancer. 2019 Apr;27(4):1345-1354. doi: 10.1007/s00520-018-4408-6. Epub 2018 Aug 11.
4
Clinical practice in febrile neutropenia risk assessment and granulocyte colony-stimulating factor primary prophylaxis of febrile neutropenia in Poland.
Contemp Oncol (Pozn). 2014;18(6):419-24. doi: 10.5114/wo.2014.47904. Epub 2014 Dec 31.
5
Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy.
Support Care Cancer. 2015 Apr;23(4):1137-43. doi: 10.1007/s00520-014-2597-1. Epub 2015 Jan 10.
6
Safety and tolerability of docetaxel, cyclophosphamide, and trastuzumab compared to standard trastuzumab-based chemotherapy regimens for early-stage human epidermal growth factor receptor 2-positive breast cancer.
J Breast Cancer. 2014 Dec;17(4):356-62. doi: 10.4048/jbc.2014.17.4.356. Epub 2014 Dec 26.
7
A modified filgrastim regimen does not reduce pain burden compared to pegfilgrastim in women receiving chemotherapy for non-metastatic breast cancer.
Support Care Cancer. 2015 Jun;23(6):1669-77. doi: 10.1007/s00520-014-2449-z. Epub 2014 Nov 26.
8
Adjuvant Docetaxel and Cyclophosphamide (DC) with prophylactic granulocyte colony-stimulating factor (G-CSF) on days 8 &12 in breast cancer patients: a retrospective analysis.
PLoS One. 2014 Oct 15;9(10):e107273. doi: 10.1371/journal.pone.0107273. eCollection 2014.
9
Comparison of pegfilgrastim prescribing practice to national guidelines at a university hospital outpatient oncology clinic.
J Oncol Pract. 2013 Jul;9(4):203-6. doi: 10.1200/JOP.2012.000662. Epub 2012 Nov 6.
10
Real-world impact of granulocyte-colony stimulating factor on febrile neutropenia.
Curr Oncol. 2013 Jun;20(3):e171-9. doi: 10.3747/co.20.1306.
本文引用的文献
1
Impact of diabetes mellitus on complications and outcomes of adjuvant chemotherapy in older patients with breast cancer.
J Clin Oncol. 2009 May 1;27(13):2170-6. doi: 10.1200/JCO.2008.17.5935. Epub 2009 Mar 23.
2
Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735.
J Clin Oncol. 2009 Mar 10;27(8):1177-83. doi: 10.1200/JCO.2008.18.4028. Epub 2009 Feb 9.
3
Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials.
Lancet. 2008 Jan 5;371(9606):29-40. doi: 10.1016/S0140-6736(08)60069-0.
4
Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials.
J Clin Oncol. 2008 Jan 1;26(1):44-53. doi: 10.1200/JCO.2007.11.3787.
5
Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection.
Ann Intern Med. 2007 Sep 18;147(6):400-11. doi: 10.7326/0003-4819-147-6-200709180-00010.
6
Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.
J Clin Oncol. 2006 Dec 1;24(34):5381-7. doi: 10.1200/JCO.2006.06.5391.
7
2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.
J Clin Oncol. 2006 Jul 1;24(19):3187-205. doi: 10.1200/JCO.2006.06.4451. Epub 2006 May 8.
8
Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer.
JAMA. 2005 Mar 2;293(9):1073-81. doi: 10.1001/jama.293.9.1073.
Zotero 插件